Xizhi, Taiwan

Yu-Shen Hsu

USPTO Granted Patents = 5 

 

 

Average Co-Inventor Count = 3.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Taipei County, TW (2012)
  • New Taipei, TW (2015)
  • Xizhi, TW (2012 - 2020)

Company Filing History:


Years Active: 2012-2020

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Innovations and Contributions of Inventor Yu-Shen Hsu

Introduction

Yu-Shen Hsu is a notable inventor based in Xizhi, Taiwan, recognized for his significant contributions to the field of biotechnology. With a total of five patents to his name, Hsu has made remarkable advancements in vaccine development and antibody technology.

Latest Patents

One of Hsu's latest patents involves the use of a detoxified recombinant heat-labile enterotoxin mutant, LTS61K, as a carrier protein for polysaccharide conjugation. This innovative approach aims to create vaccines that induce higher polysaccharide-specific IgG titers and greater bactericidal activity compared to traditional methods. Another significant invention is the bispecific T-cell activator antibody, which features unique linker-hinge interface domains that enhance the biological activities of linked molecules. This invention is crucial for activating T-lymphocytes without significant proliferation, showcasing Hsu's expertise in immunology.

Career Highlights

Hsu has worked with prominent organizations such as the Development Center for Biotechnology and DCB-USA LLC. His work in these institutions has allowed him to further his research and development efforts in the biotechnology sector.

Collaborations

Hsu has collaborated with esteemed colleagues, including Ta-Tung Yuan and Young-Sun Lin, contributing to the advancement of innovative solutions in his field.

Conclusion

Yu-Shen Hsu's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in vaccine and antibody technology. His work continues to impact the field significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…